全文获取类型
收费全文 | 5103篇 |
免费 | 340篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 309篇 |
妇产科学 | 75篇 |
基础医学 | 442篇 |
口腔科学 | 135篇 |
临床医学 | 434篇 |
内科学 | 1187篇 |
皮肤病学 | 133篇 |
神经病学 | 319篇 |
特种医学 | 141篇 |
外国民族医学 | 1篇 |
外科学 | 892篇 |
综合类 | 97篇 |
一般理论 | 3篇 |
预防医学 | 270篇 |
眼科学 | 165篇 |
药学 | 417篇 |
中国医学 | 16篇 |
肿瘤学 | 320篇 |
出版年
2023年 | 60篇 |
2022年 | 63篇 |
2021年 | 248篇 |
2020年 | 166篇 |
2019年 | 178篇 |
2018年 | 212篇 |
2017年 | 148篇 |
2016年 | 166篇 |
2015年 | 204篇 |
2014年 | 279篇 |
2013年 | 305篇 |
2012年 | 466篇 |
2011年 | 428篇 |
2010年 | 234篇 |
2009年 | 218篇 |
2008年 | 246篇 |
2007年 | 292篇 |
2006年 | 273篇 |
2005年 | 235篇 |
2004年 | 190篇 |
2003年 | 187篇 |
2002年 | 152篇 |
2001年 | 62篇 |
2000年 | 47篇 |
1999年 | 39篇 |
1998年 | 21篇 |
1997年 | 14篇 |
1996年 | 16篇 |
1995年 | 20篇 |
1994年 | 10篇 |
1993年 | 12篇 |
1992年 | 17篇 |
1991年 | 17篇 |
1990年 | 13篇 |
1989年 | 16篇 |
1988年 | 21篇 |
1987年 | 11篇 |
1986年 | 17篇 |
1985年 | 15篇 |
1984年 | 19篇 |
1983年 | 13篇 |
1982年 | 8篇 |
1979年 | 8篇 |
1978年 | 9篇 |
1976年 | 10篇 |
1975年 | 7篇 |
1973年 | 13篇 |
1971年 | 6篇 |
1970年 | 6篇 |
1967年 | 6篇 |
排序方式: 共有5461条查询结果,搜索用时 15 毫秒
1.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
2.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献3.
Camryn Harvie Steven J. Weissbart Priyanka Kadam‐Halani Hengyi Rao Lily A. Arya 《Clinical anatomy (New York, N.Y.)》2019,32(1):13-19
Several studies have used a variety of neuroimaging techniques to measure brain activity during the voiding phase of micturition. However, there is a lack of consensus on which regions of the brain are activated during voiding. The aim of this meta‐analysis is to identify the brain regions that are consistently activated during voiding in healthy adults across different studies. We searched the literature for neuroimaging studies that reported brain co‐ordinates that were activated during voiding. We excluded studies that reported co‐ordinates only for bladder filling, during pelvic floor contraction only, and studies that focused on abnormal bladder states such as the neurogenic bladder. We used the activation‐likelihood estimation (ALE) approach to create a statistical map of the brain and identify the brain co‐ordinates that were activated across different studies. We identified nine studies that reported brain activation during the task of voiding in 91 healthy subjects. Together, these studies reported 117 foci for ALE analysis. Our ALE map yielded six clusters of activation in the pons, cerebellum, insula, anterior cingulate cortex (ACC), thalamus, and the inferior frontal gyrus. Regions of the brain involved in executive control (frontal cortex), interoception (ACC, insula), motor control (cerebellum, thalamus), and brainstem (pons) are involved in micturition. This analysis provides insight into the supraspinal control of voiding in healthy adults and provides a framework to understand dysfunctional voiding. Clin. Anat., 2018. © 2018 Wiley Periodicals, Inc. 相似文献
4.
5.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
6.
Praerna H. Bhargav Preethi V. Reddy Ramajayam Govindaraj Kankan Gulati Arya Ravindran D. Gayathri Sneha J. Karmani Kaviraja Udupa Ganesan Venkatasubramanian Mariamma Philip Monojit Debnath Rose Dawn Bharath T. N. Sathyaprabha Bangalore N. Gangadhar Kesavan Muralidharan 《Revue canadienne de psychiatrie》2021,66(2):179
7.
8.
9.
Gupta Tejpal Maitre Madan Gupta Priyamvada Krishnatry Rahul Chatterjee Abhishek Moiyadi Aliasgar Shetty Prakash Singh Vikas Chinnaswamy Girish Epari Sridhar Sahay Ayushi Patil Vijay GodaSastri Jayant 《Journal of neuro-oncology》2020,147(2):405-415
Journal of Neuro-Oncology - To report clinical outcomes of salvage re-irradiation (re-RT) in recurrent/progressive ependymoma. Medical records of patients treated with curative-intent re-RT as... 相似文献
10.